ACM
RGLS

Asymmetry Capital Management’s Regulus Therapeutics RGLS Stock Holding History

Asymmetry Capital Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$860K Buy
273,104
+132,955
+95% +$591K 0.46% 23
2021
Q3 		$968K Sell
140,149
-4,929
-3% -$36.1K 0.58% 27
2021
Q2 		$1.18M Sell
145,078
-53,469
-27% -$597K 0.81% 28
2021
Q1 		$3.1M Buy
+198,547
New +$2.94M 1.6% 24

Other funds holding RGLS

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Asymmetry Capital Management's RGLS Position: Q4 2021 in Review

Asymmetry Capital Management increased its Regulus Therapeutics (RGLS) stake by 95% in Q4 2021, buying an estimated $591K and bringing the position to 273,104 shares worth $860K. The position accounts for 0.46% of the portfolio, ranked #23.

Asymmetry Capital Management first reported a position in RGLS in Q1 2021 and has held it in 4 quarters since. The position peaked at $3.1M in Q1 2021. 37 funds tracked by Wall St. Rank hold RGLS as of Q4 2021.

  • Asymmetry Capital Management held 273,104 shares of Regulus Therapeutics worth $860K as of Q4 2021.
  • Asymmetry Capital Management bought 132,955 Regulus Therapeutics shares in Q4 2021, an estimated $591K.
  • Regulus Therapeutics made up 0.46% of Asymmetry Capital Management's portfolio in Q4 2021, its #23 holding.
  • Asymmetry Capital Management first reported a position in Regulus Therapeutics in Q1 2021 and has held it in 4 quarters since.
  • Asymmetry Capital Management's Regulus Therapeutics position peaked at $3.1M in Q1 2021.
  • 37 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2021.

Based on Asymmetry Capital Management's 13F filing for Q4 2021, filed 19 Jan 2022.